Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro

Robert T Dorr, Nancy G. Shipp

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Neonatal rat heart myocytes were cultured in plastic 24-well plates for 6 days over which time ATP and protein levels steadily increased. Synchronous beating rates of 40-50 per min are obtained 3 days after plating 1.14 × 106 myocytes/well. The addition of rat interferon (IFN) or recombinant human interleukin (IL-2) or tumor necrosis factor (TNF) at concentrations of 10-1000 U/ml for 24-48 h did not reduce ATP/protein ratios or significantly affect beating rates. A 6-h exposure to doxorubicin concentrations of 0.5 μg/ml and 1.0 μg/ml reduced control ATP/protein ratios of 6.8-7.3 ng/gmg by 78% and 40%, respectively. Importantly, the addition of 100 U/ml of IL-2, TNF or IFN to these doxorubicin concentrations did not alter doxorubicin-induced cardiotoxicity. These results suggest that IL-2, TNF and IFN do not cause direct myocardial cell damage and may be cautiously combined with doxorubicin without enhanced cardiotoxic effects. The reported cardiotoxicity from such cytokines may be principally due to peripheral vascular effects which reflexly stress the heart.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalImmunopharmacology
Volume18
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Doxorubicin
Interferons
Interleukin-2
Cell Survival
Tumor Necrosis Factor-alpha
Adenosine Triphosphate
Muscle Cells
Proteins
Plastics
Blood Vessels
Cytokines
Cardiotoxicity
In Vitro Techniques

Keywords

  • Cardiotoxicity
  • Doxorubicin
  • Heart
  • Interferon
  • Interleukin
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro. / Dorr, Robert T; Shipp, Nancy G.

In: Immunopharmacology, Vol. 18, No. 1, 1989, p. 31-38.

Research output: Contribution to journalArticle

@article{670d9ff8b68f424bbc11e852ea557d3d,
title = "Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro",
abstract = "Neonatal rat heart myocytes were cultured in plastic 24-well plates for 6 days over which time ATP and protein levels steadily increased. Synchronous beating rates of 40-50 per min are obtained 3 days after plating 1.14 × 106 myocytes/well. The addition of rat interferon (IFN) or recombinant human interleukin (IL-2) or tumor necrosis factor (TNF) at concentrations of 10-1000 U/ml for 24-48 h did not reduce ATP/protein ratios or significantly affect beating rates. A 6-h exposure to doxorubicin concentrations of 0.5 μg/ml and 1.0 μg/ml reduced control ATP/protein ratios of 6.8-7.3 ng/gmg by 78{\%} and 40{\%}, respectively. Importantly, the addition of 100 U/ml of IL-2, TNF or IFN to these doxorubicin concentrations did not alter doxorubicin-induced cardiotoxicity. These results suggest that IL-2, TNF and IFN do not cause direct myocardial cell damage and may be cautiously combined with doxorubicin without enhanced cardiotoxic effects. The reported cardiotoxicity from such cytokines may be principally due to peripheral vascular effects which reflexly stress the heart.",
keywords = "Cardiotoxicity, Doxorubicin, Heart, Interferon, Interleukin, Tumor necrosis factor",
author = "Dorr, {Robert T} and Shipp, {Nancy G.}",
year = "1989",
doi = "10.1016/0162-3109(89)90028-3",
language = "English (US)",
volume = "18",
pages = "31--38",
journal = "Immunopharmacology",
issn = "0162-3109",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro

AU - Dorr, Robert T

AU - Shipp, Nancy G.

PY - 1989

Y1 - 1989

N2 - Neonatal rat heart myocytes were cultured in plastic 24-well plates for 6 days over which time ATP and protein levels steadily increased. Synchronous beating rates of 40-50 per min are obtained 3 days after plating 1.14 × 106 myocytes/well. The addition of rat interferon (IFN) or recombinant human interleukin (IL-2) or tumor necrosis factor (TNF) at concentrations of 10-1000 U/ml for 24-48 h did not reduce ATP/protein ratios or significantly affect beating rates. A 6-h exposure to doxorubicin concentrations of 0.5 μg/ml and 1.0 μg/ml reduced control ATP/protein ratios of 6.8-7.3 ng/gmg by 78% and 40%, respectively. Importantly, the addition of 100 U/ml of IL-2, TNF or IFN to these doxorubicin concentrations did not alter doxorubicin-induced cardiotoxicity. These results suggest that IL-2, TNF and IFN do not cause direct myocardial cell damage and may be cautiously combined with doxorubicin without enhanced cardiotoxic effects. The reported cardiotoxicity from such cytokines may be principally due to peripheral vascular effects which reflexly stress the heart.

AB - Neonatal rat heart myocytes were cultured in plastic 24-well plates for 6 days over which time ATP and protein levels steadily increased. Synchronous beating rates of 40-50 per min are obtained 3 days after plating 1.14 × 106 myocytes/well. The addition of rat interferon (IFN) or recombinant human interleukin (IL-2) or tumor necrosis factor (TNF) at concentrations of 10-1000 U/ml for 24-48 h did not reduce ATP/protein ratios or significantly affect beating rates. A 6-h exposure to doxorubicin concentrations of 0.5 μg/ml and 1.0 μg/ml reduced control ATP/protein ratios of 6.8-7.3 ng/gmg by 78% and 40%, respectively. Importantly, the addition of 100 U/ml of IL-2, TNF or IFN to these doxorubicin concentrations did not alter doxorubicin-induced cardiotoxicity. These results suggest that IL-2, TNF and IFN do not cause direct myocardial cell damage and may be cautiously combined with doxorubicin without enhanced cardiotoxic effects. The reported cardiotoxicity from such cytokines may be principally due to peripheral vascular effects which reflexly stress the heart.

KW - Cardiotoxicity

KW - Doxorubicin

KW - Heart

KW - Interferon

KW - Interleukin

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0024401848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024401848&partnerID=8YFLogxK

U2 - 10.1016/0162-3109(89)90028-3

DO - 10.1016/0162-3109(89)90028-3

M3 - Article

VL - 18

SP - 31

EP - 38

JO - Immunopharmacology

JF - Immunopharmacology

SN - 0162-3109

IS - 1

ER -